VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | Overcoming resistance to IO with sitravatinib + tocilizumab in patients with lung cancer

Qing Zhou, MD, PhD, of the Guangdong Lung Cancer Institute, Guangzhou, China, discusses the results of a Phase I clinical trial investigating the combination of sitravatinib with tocilizumab in order to overcome resistance to checkpoint blockade therapies. Promising findings from this study have resulted in a randomized Phase III trial currently underway. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter